AUA 2018: Overview of Immunotherapy in GU Cancers – UroToday
|
AUA 2018: Overview of Immunotherapy in GU Cancers
UroToday Currently, in prostate cancer, only one approved immunotherapy exists, Sipuleucel-T, for patients with minimally symptomatic or asymptomatic metastatic castrate resistant prostate cancer. However, the Society for Immunotherapy of Cancer Consensus (SITC … |
